Jessica Thrush
Researcher
Also affiliated: University of Siena (2021); Watford General Hospital (2023); Airedale General Hospital (2023); North Manchester General Hospital (2021); Glenfield Hospital (2019); British Heart Foundation (2019); Worcestershire Royal Hospital (2021–2023); Alexandra Hospital (2021–2023); NIHR Leicester Cardiovascular Biomedical Research Unit (2019)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jessica Thrush's research investigates the clinical management and treatment of COVID-19, with a focus on organ support-free days and the potential benefits of interventions such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and intravenous vitamin C. Her work also extends to the pharmacological effects of synthetic cannabinoid receptor agonists, specifically their interaction with fentanyl and naloxone in preclinical models. Thrush has published 18 articles, accumulating over 4,900 citations, and holds an h-index of 14. She has collaborated with researchers at the University of Arkansas for Medical Sciences, including William E. Fantegrossi, Jeffery H. Moran, Marina Avram, and Hannah E. Shaw. Her recent activity indicates ongoing contributions to medical research.
Metrics
- h-index: 14
- Publications: 18
- Citations: 5,123
Selected Publications
-
Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice (2025)
Collaboration Network
Top Collaborators
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
Similar Researchers
Based on overlapping research topics